<DOC>
	<DOCNO>NCT02836340</DOCNO>
	<brief_summary>Following successful cardiopulmonary resuscitation ( CPR ) hospital cardiac arrest ( OHCA ) , 50 % patient admit Intensive Care Unit ( ICU ) die . As patient die due brain damage sustain cardiac arrest subsequent reperfusion phase , effective neuroprotective strategy could potentially improve outcome . In animal experiment , 2-Iminobiotin ( 2-IB ) , selective neuronal inducible nitric oxide synthase ( NOS ) inhibitor , give upon reperfusion show improve memory function . Since 2-IB show safety issue preclinical clinical study . Before embark large study efficacy primary endpoint , safety , tolerability pharmacokinetics need establish . Objective : Evaluate short term safety tolerability , pharmacokinetic property 2-IB adult patient OHCA . Study design : Phase 2 , single-centre , open-label , dose-escalation intervention study . Study population : Three cohort eight evaluable patient admit ICU OHCA due cardiac cause . Intervention : The first eight patient receive 0,055 mg/kg 2-IB every 4 hour intravenously , 6 time total ( part A ) . The second eight patient ( cohort B ) receive 0,165 mg/kg every 4h iv , 6 time total . The third eight patient ( cohort C ) receive 0,5 mg/kg every 4h iv , 6 time total . Medication give soon possible within 6h OHCA . Escalation next dose level do pharmacokinetic analysis perform , relevant safety issue encounter , DSMB approve move next dose level . Main study parameters/endpoints : Study parameter evaluate short term safety tolerability vital sign ( heart frequency , blood pressure , cardiac ischemia ) 15 minute administration . ( Serious ) Adverse Events record ICU ( 7 day ) discharge ICU . For evaluation pharmacokinetics profile 2-IB , 9 plasma sample analyse . Secondary parameter : Biochemical marker Neuron specific Enolase s100b 24h 48h start study drug , occurrence SAEs 30 day OHCA include death , long term term efficacy determine Cerebral Performance Category ( CPC ) , Informant Questionnaire Cognitive Decline Elderly ( IQCODE ) Telephone Interview Cognitive Status ( TICS ) scale 30 day OHCA .</brief_summary>
	<brief_title>TIBOHCA : Safety , Tolerability Pharmacokinetics 2-Iminobiotin ( 2-IB ) After OHCA</brief_title>
	<detailed_description>Objective : The primary objective study evaluate short term safety tolerability , pharmacokinetic property 2-IB administered adult patient OHCA . Study design : A Phase 2 , single-centre , open-label , dose-escalation intervention study . Study population : The study population constitute three cohort eight evaluable patient admit ICU CPR OHCA due cardiac cause . Intervention : The first cohort eight patient receive 2-IB dose 0,055 mg/kg/dose every 4 h iv , 6 time total ( part A ) . The second cohort eight patient ( cohort B ) receive anticipate dose 0,165 mg/kg/dose every 4h iv , 6 time total , third cohort eight patient ( cohort C ) receive anticipate dose 0,500 mg/kg/dose every 4h iv , 6 time total . The first dose give soon possible within 6h OHCA . Escalation next dose level do pharmacokinetic analysis perform , relevant safety issue encounter , DSMB approve move next dose level . Main study parameters/endpoints : The main study parameter use evaluate short term safety tolerability vital sign ( heart frequency , blood pressure , cardiac ischemia ) 15 minute administration study drug need intervention . Furthermore , biochemistry haematology take part standard clinical care assess , occurrence ( Serious ) Adverse Events ( ( S ) AEs ) 7 day ICU discharge ICU , whichever occur early . For evaluation pharmacokinetics profile 2-IB , 9 plasma sample analyse . Pharmacokinetic parameter determine include Cmax , AUC , Tmax , t1/2 , clearance ( Cl ) , volume distribution ( Vd ) . Secondary parameter : 1 . Short term efficacy determine biochemical marker NSE s100b 24h 48h start first infusion study drug . 2 . Longer term safety determine occurrence SAEs 30 day OHCA include death . 3 . Longer term efficacy determine Cerebral Performance Category ( CPC ) , Computer Assisted Mild Cognitive Impairment ( CAMCI ) score , Informant Questionnaire Cognitive Decline Elderly ( IQCODE ) alternatively Telefonisch Interview Cognitieve Status ( TICS ) scale ( telephone ) 30 day OHCA .</detailed_description>
	<mesh_term>Brain Injuries</mesh_term>
	<mesh_term>Heart Arrest</mesh_term>
	<mesh_term>Out-of-Hospital Cardiac Arrest</mesh_term>
	<mesh_term>Hypoxia-Ischemia , Brain</mesh_term>
	<criteria>Admission ICU OHCA successful CPR due cardiac cause Post anoxic coma admission Ability start study medication soon possible , ultimately within 6h OHCA via central venous line Age 18 year older Eligible treatment target temperature management 36‚Å∞ C No informed consent Known comorbidity life expectancy &lt; 6 month prior cardiac arrest Women age 49 less Severe cognitive impairment ( documented dementia ) know prior OHCA Inability insert central venous line</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>neuroprotection</keyword>
</DOC>